Background/Objective: Cesarean scar pregnancy (CSP) represents a challenging and potentially life-threatening form of ectopic pregnancy. This study aims to assess the feasibility, safety, and clinical efficacy of employing the hysteroscopic mechanical tissue removal system as a primary treatment modality for CSP. Methods: This retrospective cohort study included 53 patients diagnosed with CSP who underwent primary hysteroscopic resection at a tertiary care center. The surgical procedure was performed by prioritizing the “no-touch” vaginoscopic approach, which avoids instrumentation. Success rates, operation time, time to negative serum β-hCG, complications, and differences between the anatomical types of CSP (Type 1 vs. Type 2) were analyzed. Results: Primary hysteroscopic treatment was successful in 51 of 53 patients (96.2%). For the entire cohort, the median operative time was 7 min (range: 2–30), and the median interval to β-hCG negativization was 11 days (range: 6–45). The overall major complication rate was 3.8% (n = 2). One case was deemed unsuccessful due to conversion to laparotomy following uterine perforation during cervical dilation. Another patient, diagnosed with persistent trophoblastic disease requiring methotrexate (MTX) therapy, was also considered a treatment failure. Operative time was significantly longer in patients with Type II CSP compared with Type I (median 9 min vs. 5 min; p = 0.0004). Conclusions: Hysteroscopic mechanical tissue removal as a primary treatment for cesarean scar pregnancy represents an effective and safe “one-step” approach, characterized by a high success rate, rapid β-hCG resolution, and a low incidence of complications. This fertility-preserving, minimally invasive technique may be considered a primary treatment option for hemodynamically stable patients with CSP, provided that appropriate patient selection is undertaken and sufficient surgical expertise is available.
30 September 2020 in Eurasian Journal of Family Medicine
Aim: The aim of this study was to compare vitamin D levels between pregnant women with hyperemesis gravidarum before 12 weeks of gestation and healthy pregnant women at similar ages. Methods: Sixty pregnancies with hyperemesis gravidarum and 60 age compatible healthy pregnancies applied to our facility were included in the study. Demographic characteristics, maternal thyroid function tests and 25-Hydroxyvitamin D levels were evaluated. Student t test was used for the variables with normal distribution and Mann-Whitney U test was used to analyze the variables without normal distribution. Results: Only one pregnant woman had normal vitamin D levels (>30ng/ml), whereas 71 patients had deficiency (10-30 ng/ml), and 48 had severe deficiency (
Amaç : Amacımız, dehidroepiandrosteronun (DHEA) doksorubisine bağlı over hasarı üzerinde koruyucu bir etkisi olup olmadığını değerlendirmektir. Gereç ve Yöntem:Ratlar üç gruba ayrıldı. Grup 1 (kontrol grubu) tedavi uygulanmadı. Sağlam over dokusu çıkarıldı ve Anti-Mulleran Hormon (AMH) testi için kan örnekleri alındı. Grup 2 (doksorubisin grubu), ratlara 3 mg/kg'lık tek bir dozda intraperitonal yoldan doksorubisin verildi. Grup 3 (doksorubisin + DHEA grubu), ratlara intraperitonal yolla 3 mg/kg'lık tek bir dozda ve günde 60 mg / kg'lık bir dozda subcutan DHEA'ya ilaveten tek doz doz doksorubisin verildi. Grup 2 ve 3'teki ratların onuncu günün sonunda yumurtalık dokuları alındı ve AMH testi için kan örnekleri alındı. Bulgular: Normal over doku hasarı skorları kanama dışında sıfır olmakla birlikte, doksorubisin tüm deneklerde anlamlı hasar ve histopatolojik değişiklikler gösterdi. Doksorubisin ve Doksorubisin + DHEA gruplarında normal over grubundan daha yüksek ödem, vasküler konjesyon, hücresel dejenerasyon ve toplam hasar skorları vardı. Antral folikül sayısı ve yumurtalık hacmi doksorubisin grubunda normal over grubuna göre azaldı (sırasıyla p = 0.011 ve 0.002). Doksorubisin + DHEA grubundaki over hacmi, normal over hacmine benzerdi (p = 0.091), ancak antral folikül sayısı bu grupta anlamlı olarak daha düşüktü (p = 0.002). AMH değerleri normal over grubu ile diğer gruplar arasında farklılık göstermedi. Sonuç : DHEA'nın doksorubisinin neden olduğu over hasarını önlemede etkili olmadığı sonucuna varıldı. Objective: Our aim is to evaluate whether dehydroepiandrosterone has a protective effect on doxorubicin-induced ovarian damage. Methods: Group 1 (the control Group): no treatment was administered. Intact ovarian tissue was removed, and blood samples were taken for anti-Mullerian hormone (AMH) test. Group 2 (the doxorubicin Group): Rats received doxorubicin intraperitoneally at a single dose of 3 mg / kg. Group 3 (the doxorubicin + DHEA Group): Rats received doxorubicin intraperitoneally at a single dose of 3 mg / kg at baseline and DHEA subcutaneously for 10 days at a dose of 60 mg / kg daily. Rats in groups 2 and 3 were sacrificed at the end of 10 days, ovarian tissues were removed and blood samples were taken for AMH test. Results: While normal ovarian tissue damage scores were zero except hemorrhage, doxorubicin showed significant damage and histopathological changes in all rats. Doxorubicin and Doxorubicin + DHEA groups had higher edema, vascular congestion, cellular degeneration and total damage scores than the normal ovarian group. The number of antral follicles and ovarian volume decreased in the doxorubicin group compared to the normal ovarian group (p = 0.011 and 0.002, respectively). In the doxorubicin + DHEA group, ovarian volume was similar to normal ovary (p = 0.091), but the number of antral follicles was significantly lower in this group (p = 0.002). AMH values did not differ between the normal ovarian group and the other groups. Conclusion: It was concluded that DHEA was not effective in preventing ovarian damage caused by doxorubicin.